Where is fxr located

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: FXR, or Farnesoid X Receptor, is a nuclear receptor protein primarily located in the liver, intestines, and kidneys. It was first identified in 1995 and plays a crucial role in regulating bile acid metabolism, glucose homeostasis, and lipid metabolism. In the liver, FXR is expressed in hepatocytes and cholangiocytes, where it helps maintain bile acid balance and prevent toxicity.

Key Facts

FXR was first discovered and cloned in 1995 by researchers studying nuclear receptors
FXR is encoded by the NR1H4 gene located on chromosome 12q23.1 in humans
FXR activation can reduce serum triglycerides by up to 50% in animal models
FXR regulates approximately 200-300 genes involved in metabolic processes
FXR agonists like obeticholic acid received FDA approval in 2016 for treating primary biliary cholangitis

Overview

The Farnesoid X Receptor (FXR), also known as the bile acid receptor, is a nuclear receptor that plays a pivotal role in metabolic regulation. First identified in 1995 during research on orphan nuclear receptors, FXR was named for its initial activation by farnesol, though it was later discovered that bile acids are its primary endogenous ligands. This receptor belongs to the NR1H subfamily of nuclear receptors and functions as a transcription factor that regulates gene expression in response to binding with specific molecules.

FXR is predominantly expressed in tissues involved in bile acid metabolism and energy homeostasis, with the highest concentrations found in the liver, intestines, and kidneys. The receptor's discovery marked a significant advancement in understanding how the body maintains bile acid balance and prevents toxicity from bile acid accumulation. Since its identification, FXR has become a major therapeutic target for various metabolic disorders, including liver diseases, diabetes, and hyperlipidemia, with several pharmaceutical compounds now in development or clinical use.

How It Works

FXR functions as a ligand-activated transcription factor that regulates numerous metabolic pathways through complex molecular mechanisms.

Ligand Binding and Activation: FXR is primarily activated by bile acids, particularly chenodeoxycholic acid (CDCA), which binds to the receptor with an EC50 of approximately 10-50 μM. Upon binding, FXR undergoes conformational changes that allow it to form heterodimers with retinoid X receptor (RXR) and translocate to the nucleus.
Gene Regulation Mechanism: The FXR-RXR complex binds to specific DNA sequences called FXR response elements (FXREs) in the promoter regions of target genes. This binding recruits co-activators or co-repressors to modulate gene transcription, regulating approximately 200-300 genes involved in bile acid synthesis, transport, and metabolism.
Bile Acid Homeostasis: FXR activation suppresses bile acid synthesis by downregulating cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in the classic bile acid synthesis pathway. Simultaneously, it upregulates bile salt export pump (BSEP) expression, increasing bile acid excretion from hepatocytes into bile canaliculi.
Metabolic Cross-Talk: FXR interacts with other nuclear receptors and signaling pathways, including the fibroblast growth factor 19 (FGF19) pathway in the intestine. When intestinal FXR is activated by bile acids, it stimulates FGF19 secretion, which travels to the liver to further suppress CYP7A1 expression, creating a negative feedback loop.

Key Comparisons

Feature	FXR (NR1H4)	Other Nuclear Receptors
Primary Ligands	Bile acids (CDCA, DCA)	Steroids, fatty acids, vitamins
Tissue Distribution	Liver, intestine, kidney	Varies by receptor type
Metabolic Functions	Bile acid, lipid, glucose metabolism	Specific to ligand type
Discovery Year	1995	Varies (PPARγ: 1990, LXR: 1994)
Therapeutic Applications	Liver diseases, metabolic disorders	Cancer, inflammation, metabolism

Why It Matters

Liver Disease Treatment: FXR agonists like obeticholic acid have shown significant efficacy in treating primary biliary cholangitis, with clinical trials demonstrating improvement in biochemical markers in approximately 50-70% of patients. These drugs represent a new class of therapeutics for cholestatic liver diseases that were previously difficult to manage.
Metabolic Syndrome Management: FXR activation improves insulin sensitivity and reduces hepatic gluconeogenesis, making it a promising target for type 2 diabetes treatment. Studies show FXR agonists can reduce fasting blood glucose by 15-25% in animal models of diabetes and improve glucose tolerance in human clinical trials.
Cardiovascular Protection: By regulating lipid metabolism, FXR activation reduces serum triglycerides by up to 50% in preclinical studies and decreases atherosclerosis progression. This positions FXR as a potential therapeutic target for cardiovascular diseases associated with dyslipidemia.

The continued research into FXR biology and pharmacology holds tremendous promise for developing novel treatments for a wide range of metabolic disorders. As our understanding of FXR's complex regulatory networks deepens, we can expect more targeted therapies with fewer side effects. Future directions include tissue-specific FXR modulators, combination therapies with other nuclear receptor agonists, and personalized approaches based on genetic variations in FXR signaling pathways. The next decade will likely see expanded clinical applications beyond liver diseases to include diabetes, obesity, and cardiovascular conditions, potentially benefiting millions of patients worldwide.